Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year
With Exits Down, So Are New Financings
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
